Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Change in Accured Expenses (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Change in Accured Expenses for 11 consecutive years, with $6.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses changed N/A to $6.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.7 million, a N/A change, with the full-year FY2025 number at $5.4 million, up 3333.7% from a year prior.
  • Change in Accured Expenses was $6.3 million for Q4 2025 at Crescent Biopharma, up from -$720283.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $6.3 million in Q4 2025 to a low of -$2.9 million in Q1 2025.
  • A 5-year average of -$192196.4 and a median of -$449503.5 in 2021 define the central range for Change in Accured Expenses.
  • Biggest YoY gain for Change in Accured Expenses was 149.06% in 2022; the steepest drop was 850.29% in 2022.
  • Crescent Biopharma's Change in Accured Expenses stood at $881616.0 in 2021, then skyrocketed by 33.89% to $1.2 million in 2022, then crashed by 107.27% to -$85820.0 in 2023, then plummeted by 1435.44% to -$1.3 million in 2024, then soared by 578.93% to $6.3 million in 2025.
  • Per Business Quant, the three most recent readings for CBIO's Change in Accured Expenses are $6.3 million (Q4 2025), -$720283.0 (Q2 2025), and -$2.9 million (Q1 2025).